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Adult muscle carnitine palmitoyltransferase (CPT) II deficiency is a rare autosomal
recessive disorder of long-chain fatty acid metabolism. It is typically associated with
recurrent episodes of exercise-induced rhabdomyolysis and myoglobinuria, in most
cases caused by a c.338C > T mutation in the CPT2 gene. Here we present the
pedigree of one of the largest family studies of CPT II deficiency caused by the
c.338C > T mutation, documented so far. The pedigree comprises 24 blood relatives
of the index patient, a 32 year old female with genetically proven CPT II deficiency. In
total, the mutation was detected in 20 family members, among them five homozygotes
and 15 heterozygotes. Among all homozygotes, first symptoms of CPT II deficiency
occurred during childhood. Additionally, two already deceased relatives of the index
patient were carriers of at least one copy of the genetic variant, revealing a remarkably
high prevalence of the c.338C > T mutation within the tested family. Beside the index
patient, only one individual had been diagnosed with CPT II deficiency prior to this study
and three cases of CPT II deficiency were newly detected by this family study, pointing
to a general underdiagnosis of the disease. Therefore, this study emphasizes the need
to raise awareness of CPT II deficiency for correct diagnosis and accurate management
of the disease.
Keywords: carnitine palmitoyltransferase II deficiency, family study, mutation, underdiagnosis, pedigree
INTRODUCTION
Degradation of fatty acids via mitochondrial β-oxidation is an essential pathway for energy
homeostasis, especially in situations with high energy demand and glucose limitation, such as
prolonged fasting or exercise. For β-oxidation to occur, the long-chain fatty acids have to be
transported across the mitochondrial membrane by the carnitine palmitoyltransferase (CPT)
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system, consisting of CPT I and II, located in the outer (CPT I)
and inner mitochondrial membrane (CPT II). Defects of these
enzymes, such as CPT II deficiency, disrupt β-oxidation and lead
to disorders of fatty acid metabolism (Bonnefont et al., 2004;
Houten and Wanders, 2010; Lehmann et al., 2017).
Carnitine palmitoyltransferase II deficiency is a rare
autosomal recessive hereditary disorder with three clinical
phenotypes: a lethal neonatal form, a severe infantile and a mild
adult myopathic form (Bonnefont et al., 2004; Lehmann et al.,
2017). Muscle CPT II deficiency in young adults is the most
frequent type. Patients present primarily with recurrent attacks
of myalgia and muscle weakness, associated with rhabdomyolysis
and myoglobinuria (Deschauer et al., 2005; Joshi et al., 2018).
Treatment includes avoidance of known triggers such as fasting
and excessive exercise, in addition to a low-fat/high carbohydrate
diet and in some cases L-carnitine administration (Wieser, 2017).
Diagnosis of CPT II deficiency is commonly confirmed by
sequence analysis of the CPT2 gene. The most frequent CPT2
pathogenic mutation in Caucasians is the missense variant
c.338C > T (p.Ser113Leu, rs74315294) found in up to 90% of
symptomatic patients (Joshi et al., 2014), but only in 0.1 – 0.2%
of the general European population (Sherry et al., 2001; Lek et al.,
2016). Around 60% –70% of the patients with CPT II deficiency
are homozygous for the c.338C > T mutation and remaining
others are compound heterozygotes, many of which are carrying
the common c.338C > T variant in combination with various
rarely occurring mutations of the CPT2 gene (Isackson et al.,
2006; Corti et al., 2008; Joshi et al., 2014).
Despite the knowledge of the genetic background and
advances made in non-invasive diagnosis of the disease,
CPT II deficiency is still underdiagnosed, probably due to
variable degrees of the symptomatology as well as lack of
awareness among the general public and health care professionals
(Balasubramanian et al., 2018).
Here we present the pedigree of one of the largest family
studies of CPT II deficiency caused by the c.338C > T mutation
documented so far. It includes 24 blood relatives of the index
patient, over three generations and shows a higher than expected
prevalence of this rare hereditary disease within the tested family.
CASE PRESENTATION
The index patient of this family study is a 32 year old female
from Austria, who presented with a long standing history
of myalgias and recurrent, exercise-induced rhabdomyolysis
episodes accompanied by myoglobinuria. First symptoms
occurred in childhood, around 5 years of age. After prolonged
physical activity such as hiking or skiing she experienced severe
myalgias and muscle weakness combined with dark colored
urine. At this point, however, she did not seek medical attention
and the episodes self-resolved. Several years later she moved
to Australia, where she was admitted at the age of 32, to the
acute medical unit of the Royal Adelaide Hospital (Australia) due
to severe whole-body rhabdomyolysis with myoglobinuria. Her
creatine kinase (CK) level was significantly raised to 45,560 U/L,
but her kidney function was normal. She was treated with an
intravenous fluid therapy and was kept in the hospital for the
following 5 days, where her muscles aches gradually improved
and her CK levels decreased. In her family history she reported
that her maternal uncles were also affected by recurrent episodes
of rhabdomyolysis and myoglobinuria.
A subsequent mutation analysis of the CPT2 gene using
a custom 1,037 gene Roche 1 k Disease (R1kD) Seq Cap
EZ capture kit on a NextSeq R© Sequencing System instrument
(Illumina, San Diego, CA, United States), revealed a homozygous
c.338C > T mutation, confirming the diagnosis of the suspected
adult muscular form of hereditary CPT II deficiency.
Thereupon, the Austrian family members of the index patient
were invited to take part in this family case study. All participants
gave written informed consent for genetic testing of the CPT2
c.338C > T variant as well as for their participation in the
study and for publication of this case report. Genotyping
analysis was performed by Sanger sequencing as described in
the Supplementary Material. The pedigree of the index patient
together with results from genotyping is given in Figure 1.
Sequence analysis showed that all four maternal uncles of the
index patient were homozygous for the CPT2 c.338C > T allele
(participants 8, 9, 10, and 11 in the pedigree). Information on
age at which symptoms first appeared, hospitalization due to
rhabdomyolysis, nutrition, and sports activities was obtained by
a standardized questionnaire.
All four maternal homozygous uncles aged between 57 and
61 years reported recurrent events of exercise-induced myalgia
and rhabdomyolysis of various degrees, with first symptoms
occurring during childhood, between five and eight years of age.
Prior to this study, for three of them (participant 8, 10, and 11
in the pedigree) severe whole-body rhabdomyolysis accompanied
by myoglobinuria, had led to hospitalization, at least once.
Tandem mass spectrometry analysis of a muscle biopsy sample
of participant 8 showed elevated long-chain acylcarnitine levels
(C16 and C18:1), associated with CPT II deficiency. Furthermore,
enzyme activity of CPT II in leukocytes was only at 3% of the
control value, confirming diagnosis of CPT II deficiency for
participant 8. Although a metabolic myopathy was suspected for
participants 10 and 11, no further tests were performed and CPT
II deficiency remained undiagnosed.
Moreover, one homozygous maternal uncle (participant 9)
never sought medical attention, even though he experienced
several episodes of rhabdomyolysis and myoglobinuria
throughout his life.
Furthermore, we identified 15 family members as
heterozygous carriers of the genetic variant (see pedigree).
None of them, however, reported any clinical symptoms
indicating CPT II deficiency.
The maternal grandmother of the index patient (#4 in the
pedigree) died prior to this study and could, therefore, not be
genetically tested. However, based on the established genotypes of
her children multinomial distribution revealed that the odds for a
homozygous genotype are 16 times higher as for the heterozygous
genotype (statistical considerations are described in detail in
the Supplementary Material). As for the deceased asymptotic
paternal grandfather of the index patient (#1 in the pedigree) we
assumed a heterozygous carriership to be most likely.
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FIGURE 1 | Pedigree of an Austrian family with frequent occurrence of CPT II deficiency caused by the CPT2 c.338C > T mutation. The index patient is marked with
an arrow. Genotypes of the deceased participants 1 and 4 may be assumed as heterozygous and homozygous, respectively, based on reported symptoms and
statistical considerations (as given in the Supplementary Material).
DISCUSSION
Here we reported one of the largest family studies of CPT II
deficiency documented so far. The pedigree presented in this
study comprises 24 blood relatives of the index patient over
three generations, with 20 affected individuals including five
homozygous and 15 heterozygous carriers of the c.338C > T
mutation. Additionally, two already deceased relatives of the
index patient were carriers of at least one copy of the
genetic variant.
Prior to this study, all five living homozygous family
members had experienced recurrent rhabdomyolysis events
that had led to hospitalization for four of them. However,
beside the index patient only one of them (participant
8) had been correctly diagnosed with CPT II deficiency.
Although two patients (10 and 11) sought medical care due
to recurrent episodes of myoglobinuria, CPT II deficiency
remained undiagnosed. Here, it should be noted that several
established as well as hospital physicians were involved in the
care of these patients pointing to the low awareness of the
disease, even in countries with high medical standards, like
Austria. Underdiagnosis such as this, is a known problem of
the condition (Balasubramanian et al., 2018; Gjorgjievski et al.,
2018). Many patients attribute myalgia or muscle weakness
after physical activity to lack of physical fitness and do not
seek medical advice, even when they experience myoglobinuria
events. Moreover, the condition often remains underdiagnosed
due to lack of understanding of its clinical representation
(Wieser et al., 2003).
Correct diagnosis of CPT II deficiency, however, is crucial
to prevent recurring episodes and set appropriate measures
to avert grave complications such as acute kidney injury,
should rhabdomyolysis and myoglobinuria occur. Typically,
heterozygous carriers do not show a clinical phenotype,
though cases of heterozygous carriers with mild to severe
symptoms are known (Fanin et al., 2012; Joshi et al., 2012).
In this respect, primarily the progenies of heterozygous
carries are of clinical relevance, since they are at risk
of becoming symptomatic homozygotes or compound
heterozygotes with a more serious form of the disease
(Taggart et al., 1999; Thuillier et al., 2000; Vladutiu et al.,
2002). However, genetic testing for the CPT2 c.338C > T
mutation in asymptomatic subjects is not recommended.
Detecting heterozygous carriers could cause unwarranted
social problems such as discrimination against hereditary
illness and/or refusal of acceptance for health insurance. More
importantly, psychological stress could be increased when
muscle symptoms, which are probably not caused by genetic
CPT II deficiency, occur.
On the maternal side of the index patient the number
of individuals affected by the c.338C > T mutation is
remarkably high. In fact, both maternal grandparents showed
a heterozygous or a most likely homozygous genotype. The
affected grandparents (#3 and #4 in the pedigree) on the
maternal side both originate from the same remote Austrian
village. Elevated appearance of homozygous or heterozygous
individuals of rare hereditary diseases within a secluded
population is a well-known phenomenon. Over past centuries
geographic isolation of secluded communities restricted the
genetic exchange and thereby favored the propagation of rare
autosomal recessive diseases (Zlotogora, 2007). Further insight
into the local frequency of the disease could be gained by
investigating the prevalence of CPT II deficiency in other families
originating from the same area. Particularly with regard to
the general underdiagnosis of the disease the identification of
symptomatic homozygous affected patients would contribute
to appropriate disease management and prevention of future
serious episodes.
Notably, the heterozygous father and the heterozygous mother
of the index patient (#5 and #6 in the pedigree, respectively)
originate from other regions in Austria and belong to different
religion confessions. Therefore, any relationship between the
father and the mother of the index patient appears unlikely. The
high prevalence of the CPT2 mutation within the family of the
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index patient, even in unrelated family members, may point to
a higher frequency of the CPT2 c.338C > T mutation in certain
Middle European areas than given in public mutation databases
for a Caucasian population (Sherry et al., 2001; Lek et al., 2016).
This issue may be clarified in future genome projects.
In conclusion, our study showed that CPT II deficiency
is generally underdiagnosed. Furthermore, the c.338C > T
mutation might have a higher prevalence than stated by
genetic databases, especially in populations with limited genetic
exchange. Therefore, this study emphasizes the need to expand
the awareness of CPT II deficiency in the general public and
health care professionals for correct diagnosis and accurate
management of the disease.
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